Literature DB >> 22921536

Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness?

Diogo Martins-Branco1, Ana R Esteves, Daniel Santos, Daniela M Arduino, Russell H Swerdlow, Catarina R Oliveira, Cristina Januario, Sandra M Cardoso.   

Abstract

OBJECTIVE: The aim of this work was to evaluate the role of ubiquitin-proteasome system (UPS) on mitochondrial-driven alpha-synuclein (aSN) clearance in in vitro, ex vivo and in vivo Parkinson's disease (PD) cellular models.
METHOD: We used SH-SY5Y ndufa2 knock-down (KD) cells, PD cybrids and peripheral blood mononuclear cells (PBMC) from patients meeting the diagnostic criteria for PD. We quantified aSN aggregation, proteasome activity and protein ubiquitination levels. In PBMC of PD patient population we evaluated the aSN levels in the plasma and the influence of several demographic characteristics in the above mentioned determinations.
RESULTS: We found that ubiquitin-independent proteasome activity was up-regulated in SH-SY5Y ndufa2 KD cells while a downregulation was observed in PD cybrids and PBMC. Moreover, we observed an increase in protein ubiquitination that correlates with a decrease in ubiquitin-dependent proteasome activity. Accordingly, proteasome inhibition prevented ubiquitin-dependent aSN clearance. Ubiquitin-independent proteasome activity was positively correlated with ubiquitination in PBMC. We also report a negative correlation of chymotrypsin-like activity with age in control and late-onset PD groups. Total ubiquitin content is positively correlated with aSN oligomer levels, which leads to an age-dependent increase of aSN ubiquitination in LOPD. Moreover, aSN levels are increased in the plasma of PD patients.
INTERPRETATION: aSN oligomers are ubiquitinated and we identified a ubiquitin-dependent clearance insufficiency with the accumulation of both aSN and ubiquitin. However, SH-SY5Y ndufa2 KD cells showed a significant up-regulation of ubiquitin-independent proteasomal enzymatic activity that could mean a cell rescue attempt. Moreover, we identified that UPS function is age-dependent in PBMC.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921536      PMCID: PMC4077023          DOI: 10.1016/j.expneurol.2012.08.008

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  41 in total

1.  Proteasomal function is impaired in substantia nigra in Parkinson's disease.

Authors:  K S McNaught; P Jenner
Journal:  Neurosci Lett       Date:  2001-01-19       Impact factor: 3.046

Review 2.  Degradation of oxidized proteins by the 20S proteasome.

Authors:  K J Davies
Journal:  Biochimie       Date:  2001 Mar-Apr       Impact factor: 4.079

3.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis.

Authors:  Y Tanaka; S Engelender; S Igarashi; R K Rao; T Wanner; R E Tanzi; A Sawa; V L Dawson; T M Dawson; C A Ross
Journal:  Hum Mol Genet       Date:  2001-04-15       Impact factor: 6.150

Review 4.  Protein degradation and protection against misfolded or damaged proteins.

Authors:  Alfred L Goldberg
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

Review 5.  Functional neuroanatomy of the basal ganglia in Parkinson's disease.

Authors:  Thomas Wichmann; Mahlon R DeLong
Journal:  Adv Neurol       Date:  2003

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 7.  Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease.

Authors:  Taku Hatano; Shin-ichiro Kubo; Shigeto Sato; Nobutaka Hattori
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

8.  Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells.

Authors:  Ruth Rott; Raymonde Szargel; Joseph Haskin; Vered Shani; Alla Shainskaya; Irena Manov; Esti Liani; Eyal Avraham; Simone Engelender
Journal:  J Biol Chem       Date:  2007-12-10       Impact factor: 5.157

9.  NTera 2 cells: a human cell line which displays characteristics expected of a human committed neuronal progenitor cell.

Authors:  S J Pleasure; V M Lee
Journal:  J Neurosci Res       Date:  1993-08-15       Impact factor: 4.164

10.  Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids.

Authors:  A Raquel Esteves; Daniela M Arduíno; Russell H Swerdlow; Catarina R Oliveira; Sandra M Cardoso
Journal:  Antioxid Redox Signal       Date:  2009-03       Impact factor: 8.401

View more
  20 in total

1.  The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.

Authors:  A R Esteves; M G-Fernandes; D Santos; C Januário; S M Cardoso
Journal:  Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.590

Review 2.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

3.  Genetic Analysis of FBXO2, FBXO6, FBXO12, and FBXO41 Variants in Han Chinese Patients with Sporadic Parkinson's Disease.

Authors:  Lamei Yuan; Zhi Song; Xiong Deng; Zhijian Yang; Yan Yang; Yi Guo; Hongwei Lu; Hao Deng
Journal:  Neurosci Bull       Date:  2017-03-24       Impact factor: 5.203

Review 4.  Stem Cell Transplantation and Physical Exercise in Parkinson's Disease, a Literature Review of Human and Animal Studies.

Authors:  Jaison Daniel Cucarián Hurtado; Jenny Paola Berrío Sánchez; Ramiro Barcos Nunes; Alcyr Alves de Oliveira
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

5.  In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson's disease.

Authors:  L Chansel-Debordeaux; M Bourdenx; S Dovero; V Grouthier; N Dutheil; A Espana; L Groc; C Jimenez; E Bezard; B Dehay
Journal:  Gene Ther       Date:  2017-11-16       Impact factor: 5.250

6.  Inhibition of Protein Ubiquitination by Paraquat and 1-Methyl-4-Phenylpyridinium Impairs Ubiquitin-Dependent Protein Degradation Pathways.

Authors:  Juliana Navarro-Yepes; Annadurai Anandhan; Erin Bradley; Iryna Bohovych; Bo Yarabe; Annemieke de Jong; Huib Ovaa; You Zhou; Oleh Khalimonchuk; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Mol Neurobiol       Date:  2015-09-26       Impact factor: 5.590

7.  Mechanistic Interplay Between Autophagy and Apoptotic Signaling in Endosulfan-Induced Dopaminergic Neurotoxicity: Relevance to the Adverse Outcome Pathway in Pesticide Neurotoxicity.

Authors:  Chunjuan Song; Adhithiya Charli; Jie Luo; Zainab Riaz; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Toxicol Sci       Date:  2019-06-01       Impact factor: 4.849

8.  Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice.

Authors:  Franz Marxreiter; Benjamin Ettle; Verena E L May; Hakan Esmer; Christina Patrick; Christine Lund Kragh; Jochen Klucken; Beate Winner; Olaf Riess; Jürgen Winkler; Eliezer Masliah; Silke Nuber
Journal:  Neurobiol Dis       Date:  2013-07-16       Impact factor: 5.996

9.  The Impact of Mitochondrial Fusion and Fission Modulation in Sporadic Parkinson's Disease.

Authors:  Daniel Santos; A Raquel Esteves; Diana F Silva; Cristina Januário; Sandra M Cardoso
Journal:  Mol Neurobiol       Date:  2014-09-14       Impact factor: 5.590

10.  Age-related changes in the proteostasis network in the brain of the naked mole-rat: Implications promoting healthy longevity.

Authors:  Judy C Triplett; Antonella Tramutola; Aaron Swomley; Jessime Kirk; Kelly Grimes; Kaitilyn Lewis; Miranda Orr; Karl Rodriguez; Jian Cai; Jon B Klein; Marzia Perluigi; Rochelle Buffenstein; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2015-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.